Skip Nav Destination
1-9 of 9
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)
Ahmed Sawas, MD, Helen Ma, MD, Andrei Shustov, MD, Pamela Hsu, MS, Gajanan Bhat, Mark Acosta, PharmD, Steven M. Horwitz, MD, Owen A. O'Connor, MD PhD
Blood (2019) 134 (Supplement_1): 4050.
Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians
Blood (2019) 134 (Supplement_1): 5869.
Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry
Robert Stuver, MD, Niloufer Khan, MD, Marc Schwartz, Mark Acosta, Massimo Federico, MD, Christian Gisselbrecht, Frederick Lansigan, MD, Lauren C. Pinter-Brown, MD, Barbara Pro, MD, Andrei R. Shustov, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Salvia Jain, MD
Blood (2018) 132 (Supplement 1): 2926.
The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete Remission (CR) with a Special Focus on Nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study
Steven I Park, MD, Steven M. Horwitz, MD, Francine M Foss, MD, Lauren C. Pinter-Brown, MD, Kenneth R. Carson, MD PhD, Steven T. Rosen, MD, Barbara Pro, MD, Eric D. Hsi, MD, Massimo Federico, Christian Gisselbrecht, MD, Marc Schwartz, Lisa A Bellm, Mark Acosta, Ranjana H. Advani, MD, Tatyana A Feldman, MD, Mary Jo Lechowicz, MD, Sonali M. Smith, MD, Frederick Lansigan, MD, Anil Tulpule, MD, Michael Craig, MD, John P. Greer, MD, Brad S Kahl, MD, Joseph W Leach, Neil Morganstein, MD, Carla Casulo, MD, Andrei R. Shustov, MD
Blood (2017) 130 (Supplement 1): 342.
Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study
Frederick Lansigan, MD, Steven M Horwitz, MD, Lauren C Pinter-Brown, MD, Kenneth R Carson, MD, Andrei R Shustov, MD, Steven T. Rosen, MD, Barbara Pro, MD, Eric D. Hsi, MD, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A Bellm, MIM, Mark Acosta, PharmD, Francine M. Foss, MD
Blood (2016) 128 (22): 4150.
Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.
Francine Foss, MD, Nelida Sjak-Shie, MD, PhD, Andre Goy, MD, Eric Jacobsen, MD, Ranjana Advani, MD, Mitchell Smith, MD, PhD, Rami Komrokji, MD, Kelly Pendergrass, MD, Vanessa Bolejack, MPH, Karen Watts, Mark Acosta, PharmD
Blood (2007) 110 (11): 3449.
Phase II Study of Denileukin Diftitox (ONTAK®) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL) and Poor Bone Marrow Reserve.
Myron S. Czuczman, MD, Lauren Pinter-Brown, Mary Jo Lechowicz, Nancy Bartlett, MD, Hillard Lazarus, John Lister, Andre Goy, MD, Stephen Kahanic, MD, Peter Rosen, MD, Mark Acosta, PharmD
Blood (2006) 108 (11): 4724.
Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.
Francine Foss, MD, Madeleine Duvic, MD, Larisa Geskin, MD, Joseph Anderson, MD, Pierluigi Porcu, MD, Raymond J. Hohl, MD,PhD, Maureen Cooper, MD, Jasmine M. Zain, MD, John Zic, MD, Patrica Hibberd, MD,PhD, Mark Acosta, PharmD
Blood (2006) 108 (11): 2712.
A Phase II Study of Denileukin Diftitox (Ontak®) with CHOP Chemotherapy in Patients with Newly-Diagnosed Aggressive T-Cell Lymphomas, the CONCEPT Trial: Interim Analysis.
Francine M. Foss, MD, Nelida Sjak-Shie, MD, PhD, Andre Goy, MD, Ranjana Advani, MD, Eric Jacobsen, MD, Mark Acosta, PharmD
Blood (2006) 108 (11): 2461.